Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it has published its inaugural Environmental, Social, and Governance (“ESG”) report. The report summarizes the Company’s commitment to the core principles of ESG, its performance to date, and its aspirations for the future.
“At Simulations Plus, our vision is grand – to improve global health – and we have adopted the mission of achieving this goal through innovative, science-based software and consulting solutions to optimize treatment options that will both save and improve the quality of patients’ lives,” said Shawn O’Connor, chief executive officer of Simulations Plus. “With our inaugural ESG report, we have the opportunity to detail how Simulations Plus has, since its founding in 1996, placed the highest emphasis on innovation, integrity in our operations, commitment to producing positive impacts, respect for our employees, and concern for our communities.”
Mr. O’Connor continued, “At Simulations Plus, being good corporate citizens is not a temporary pursuit for these times, rather it is at the heart of everything we do, beginning with our core mission of supporting our clients’ efforts to accelerate the development and delivery of better, safer, and more effective therapeutics with less impactful methodologies, to providing consistent and excellent return to our shareholders. I am proud to have this opportunity to show how our corporate values closely align with the important principles of sustainable investing and ESG.”
The Simulations Plus ESG report can be viewed on the Investors page of its website under Corporate Profile.